Invasive lobular carcinoma: an understudied emergent subtype of breast cancer
- 26 March 2022
- journal article
- review article
- Published by Springer Nature in Breast Cancer Research and Treatment
- Vol. 193 (2) , 253-264
Abstract
Invasive lobular carcinoma (ILC) is the second most common histologic subtype of breast cancer after invasive ductal carcinoma (IDC), accounting for 10–15% of all breast cancer cases. Although most ILCs are of the luminal A intrinsic subtype, with favorable prognostic features, conflicting literature data are available on their outcomes compared to IDC with reports suggesting a higher risk of distant recurrence after 10 years. Historically, studies have combined ILC and IDC, with outcomes largely driven by the behavior of IDC given that it represents 90% of breast cancers. However, over the past 5 years, reports of several studies aimed at understanding ILC at the clinical, cellular, and molecular levels have been published, showing that IDC and ILC are distinct entities. In this review, we highlight the unique characteristics of ILC and describe the need for dedicated ILC clinical trials.Keywords
This publication has 143 references indexed in Scilit:
- Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancerBreast Cancer Research and Treatment, 2012
- Invasive lobular breast cancer: subtypes and outcomeBreast Cancer Research and Treatment, 2012
- Breast cancer phenotype in women with TP53 germline mutations: a Li-Fraumeni syndrome consortium effortBreast Cancer Research and Treatment, 2012
- Everolimus in Postmenopausal Hormone-Receptor–Positive Advanced Breast CancerNew England Journal of Medicine, 2012
- Pathology of Breast and Ovarian Cancers among BRCA1 and BRCA2 Mutation Carriers: Results from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA)Cancer Epidemiology, Biomarkers & Prevention, 2012
- Cytosolic p120-catenin regulates growth of metastatic lobular carcinoma through Rock1-mediated anoikis resistanceJournal of Clinical Investigation, 2011
- Utility of oncotype DX risk estimates in clinically intermediate risk hormone receptor‐positive, HER2‐normal, grade II, lymph node‐negative breast cancersCancer, 2010
- Preoperative Chemotherapy: Updates of National Surgical Adjuvant Breast and Bowel Project Protocols B-18 and B-27Journal of Clinical Oncology, 2008
- Invasive ductal carcinoma and invasive lobular carcinoma of breast differ in response following neoadjuvant therapy with epidoxorubicin and docetaxel + G-CSFBreast Cancer Research and Treatment, 2006
- Metastatic pattern of infiltrating lobular carcinoma of the breast: An autopsy studyJournal of Surgical Oncology, 1991